Ron Bentsur joined Beyond Air in August 2015 and serves as a Director. Mr. Bentsur has served as Chief Executive Officer and Director of UroGen Pharma, Ltd. since August 2015. From 2009 to April 2015, Mr. Bentsur served as Chief Executive Officer and Director of Keryx Biopharmaceuticals, Inc. Mr. Bentsur’s tenure as CEO of Keryx Biopharmaceuticals culminated in the September 2014 FDA approval of Auryxia® (ferric citrate) and its December 2014 US launch. Prior to joining Keryx Biopharmaceuticals, Inc., from 2006 to 2009, Mr. Bentsur served as Chief Executive Officer of XTL Biopharmaceuticals, Ltd. Prior to that, Mr. Bentsur served as Vice President Finance and Chief Financial Officer of Keryx Biopharmaceuticals, Inc.; as Director of Technology Investment Banking at Leumi Partners Underwriters, where he was responsible for all technology and biotechnology private placement and advisory transactions; and as a New York City-based investment banker, primarily at ING Barings Furman Selz. Mr. Bentsur holds a Bachelor of Arts in Economics and Business Administration with distinction from The Hebrew University of Jerusalem and an MBA, magna cum laude, from New York University’s Stern Graduate School of Business. Mr. Bentsur also serves as Director of Stemline Therapeutics, Inc.